1. Home
  2. RLAY
  3. RLAY News

Latest Relay Therapeutics Inc. (RLAY) News on August 17, 2025

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
RLAY

Insider Monkey

2 months ago

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
RLAY

GlobeNewswire

2 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
RLAY

Insider Monkey

2 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
RLAY

GlobeNewswire

2 months ago

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
RLAY

GlobeNewswire

3 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

What Makes Relay Therapeutics (RLAY) a New Buy Stock
RLAY

Zacks

3 months ago

What Makes Relay Therapeutics (RLAY) a New Buy Stock

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now
RLAY

Insider Monkey

3 months ago

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now

Relay Therapeutics to Participate in Two Upcoming Investor Conferences
RLAY

GlobeNewswire

3 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
RLAY

Insider Monkey

3 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
RLAY

GlobeNewswire

3 months ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
RLAY

GlobeNewswire

4 months ago

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

RLAY

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 04/25/2025

Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts
RLAY

Insider Monkey

4 months ago

Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts

RLAY

MT Newswires

4 months ago

Wells Fargo Initiates Relay Therapeutics at Equalweight With $4 Price Target

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?
RLAY

Insider Monkey

4 months ago

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Top Cancer Stocks to Buy to Boost Your Portfolio's Health
RLAY

Zacks

4 months ago

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple
RLAY

Insider Monkey

4 months ago

Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!
RLAY

Insider Monkey

5 months ago

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
RLAY

Zacks

5 months ago

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
RLAY

GlobeNewswire

6 months ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings
RLAY

GuruFocus.com

6 months ago

What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings

Relay Therapeutics to Participate in Two Upcoming Investor Conferences
RLAY

GlobeNewswire

6 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
RLAY

GlobeNewswire

6 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

RLAY

MT Newswires

7 months ago

Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing

RLAY

MT Newswires

7 months ago

Relay Therapeutics Insider Sold Shares Worth $362,298, According to a Recent SEC Filing

Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
RLAY

Insider Monkey

7 months ago

Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
RLAY

Simply Wall St.

7 months ago

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
RLAY

GlobeNewswire

7 months ago

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?
RLAY

Insider Monkey

8 months ago

Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
RLAY

Zacks

8 months ago

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade

RLAY

MT Newswires

8 months ago

Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
RLAY

Insider Monkey

8 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

RLAY

MT Newswires

8 months ago

Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
RLAY

GlobeNewswire

8 months ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
RLAY

GlobeNewswire

8 months ago

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
RLAY

Zacks

8 months ago

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)

Relay Therapeutics price target lowered to $18 from $19 at Leerink
RLAY

TipRanks

8 months ago

Relay Therapeutics price target lowered to $18 from $19 at Leerink

Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?
RLAY

Insider Monkey

8 months ago

Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?

RLAY

MT Newswires

8 months ago

Relay Therapeutics Signs Global Licensing Deal With Elevar Therapeutics for Lirafugratinib

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
RLAY

GlobeNewswire

8 months ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
RLAY

GlobeNewswire

8 months ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
RLAY

Zacks

9 months ago

Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
RLAY

Zacks

9 months ago

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Relay Therapeutics to Participate in Upcoming Investor Conferences
RLAY

GlobeNewswire

9 months ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
RLAY

GlobeNewswire

9 months ago

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
RLAY

GlobeNewswire

10 months ago

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses
RLAY

Simply Wall St.

10 months ago

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses

Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
RLAY

Zacks

a year ago

Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?

Why Relay Therapeutics Plummeted by Nearly 14% Today
RLAY

Motley Fool

a year ago

Why Relay Therapeutics Plummeted by Nearly 14% Today

RLAY

MT Newswires

a year ago

Sector Update: Health Care

RLAY

MT Newswires

a year ago

Relay Therapeutics Prices $200 Million Common Stock Offering; Shares Fall Pre-Bell

Relay Therapeutics Announces Pricing of Public Offering of Common Stock
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Stock Soars on Upbeat Data From Breast Cancer Study
RLAY

Zacks

a year ago

Relay Stock Soars on Upbeat Data From Breast Cancer Study

RLAY

MT Newswires

a year ago

Jefferies Upgrades Relay Therapeutics to Buy From Hold, Price Target is $16

RLAY

MT Newswires

a year ago

Oppenheimer Downgrades Relay Therapeutics to Perform From Outperform, Price Target is $24

RLAY

MT Newswires

a year ago

Relay Therapeutics Starts $200 Million Public Share Offering

Relay Therapeutics Announces Proposed Public Offering of Common Stock
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Announces Proposed Public Offering of Common Stock

RLAY

MT Newswires

a year ago

Barclays Raises Price Target on Relay Therapeutics to $17 From $14, Keeps Overweight Rating

RLAY

MT Newswires

a year ago

Top Midday Gainers

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
RLAY

Benzinga

a year ago

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

RLAY

MT Newswires

a year ago

Relay Therapeutics Shares Rise Premarket on Positive Interim Data for RLY-2608 Breast Cancer Treatment

Relay breast cancer drug shows potential in early trial
RLAY

BioPharma Dive

a year ago

Relay breast cancer drug shows potential in early trial

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

RLAY

MT Newswires

a year ago

Oppenheimer Trims Relay Therapeutics Price Target to $24 From $25, Maintains Outperform Rating

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
RLAY

Simply Wall St.

a year ago

We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

RLAY

MT Newswires

a year ago

JMP Securities Cuts Price Target on Relay Therapeutics to $21 From $24, Maintains Market Outperform Rating

RLAY

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Relay Therapeutics to $18 From $20, Maintains Buy Rating

Caribou lays off staff; Roche walks away from Relay
RLAY

BioPharma Dive

a year ago

Caribou lays off staff; Roche walks away from Relay

RLAY

MT Newswires

a year ago

Relay Therapeutics Get Collaboration, License Deal Terminated With Genentech

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
RLAY

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
RLAY

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
RLAY

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
RLAY

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement
RLAY

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
RLAY

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake
RLAY

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

RLAY

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

RLAY

MT Newswires

a year ago

Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Relay Therapeutics to Participate in Upcoming Investor Conferences
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

RLAY

MT Newswires

a year ago

Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target

RLAY

MT Newswires

a year ago

Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating

Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
RLAY

Simply Wall St.

a year ago

Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations

Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
RLAY

GuruFocus.com

a year ago

Relay Therapeutics Outperforms Revenue Expectations in Q1 2024

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
RLAY

Zacks

a year ago

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Relay Therapeutics to Participate in Upcoming Investor Conferences
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

11 Oversold Biotech Stocks To Buy Right Now
RLAY

Insider Monkey

a year ago

11 Oversold Biotech Stocks To Buy Right Now

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
RLAY

Zacks

a year ago

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

Relay Therapeutics to Participate in Three Upcoming Investor Conferences
RLAY

GlobeNewswire

a year ago

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
RLAY

Zacks

a year ago

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

Relay Therapeutics Full Year 2023 Earnings: Beats Expectations
RLAY

Simply Wall St.

a year ago

Relay Therapeutics Full Year 2023 Earnings: Beats Expectations

RLAY

GuruFocus.com

a year ago

Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
RLAY

GlobeNewswire

a year ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Share on Social Networks: